Sanofi Pasteur MSD: The Four-Type HPV Vaccine Gardasil(R) Demonstrates Real Life Benefits
5/8/2009 1:41:24 PM
More...
|
Sanofi Pasteur MSD Release: New Results Confirm That Young Women Up To The Age Of 26 Years Can Benefit From Vaccination With Gardasil(R)
2/17/2009 2:39:11 PM
More...
|
Sanofi Pasteur MSD Release: Gardasil(R) Vaccine Honoured with International Galien Prize for Pharmaceutical Research
10/31/2008 12:33:08 PM
More...
|
Sanofi Pasteur MSD Announces Cross-Protective Effect and Prevention of Precancerous Vaginal Lesions Added to Product Information of Gardasil(R)
9/12/2008 12:00:21 PM
More...
|
Sanofi Pasteur MSD Release: Sustained High Efficacy of Gardasil(R) Against Early Cervical Lesions, Precancerous Vulvar and Vaginal Lesions, and Genital Warts in Longest Follow-up of Large Phase III Studies
3/12/2008 4:19:27 PM
More...
|
Sanofi Pasteur MSD Welcomes Sweden's Decision to Recommend and Fund Human Papillomavirus Vaccination for School Girls
2/28/2008 4:29:15 PM
More...
|
Sanofi Pasteur MSD Applies for European Approval of the First Seasonal Influenza Vaccine Delivered by Intradermal Microinjection
2/13/2008 7:55:02 AM
More...
|
Sanofi Pasteur MSD Launches New Website
5/21/2007 2:32:03 PM
More...
|
Federal Advisers Endorse 5-In-1 Vaccine
1/26/2007 2:13:56 AM
More...
|
Sanofi Pasteur MSD's Gardasil Receives Positive Opinion From European Medicine Agency
7/28/2006 4:52:09 PM
More...
|